Biogen Inc. BIIB
$198.02▲ +0.05% 24H
Super Investor & Insider
3
Fondi che lo detengono
#343
Rank consenso
4.3%
% dei portafogli
$126.5M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Samantha McLemore · Patient Capital Management | 2.6% | Reduce 34.11% | 379,741 | $69.6M |
| Sarah Ketterer · Causeway Capital Management | 0.63% | Reduce 46.12% | 280,783 | $51.5M |
| Hillman Capital Management · Hillman Capital Management | 3.76% | Reduce 3.2% | 29,540 | $5.4M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for mult…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - General
CountryUnited States
Employees7,500
TickerBIIB
Statistics
Market Cap$29.23B
Revenue (TTM)$9.89B
Net Income$1.29B
Net Margin13.1%
EPS$8.79
P/E21.50
P/S2.97
P/B1.58
EV/EBITDA8.98
ROE7.7%
Dividend Yield—
Price$198.02
Data: Twelve Data · Revenue = mcap / P/S